Llwytho...
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administ...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Endocrinol Metab (Seoul) |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Korean Endocrine Society
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4384669/ https://ncbi.nlm.nih.gov/pubmed/25827453 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2015.30.1.19 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|